DOCUMENTS

101

 

NOTICES

156

 

 

MOTS CLES

Autoimmune diseases Albinism Biological Therapy Artificial intelligence Accelerometer Prostate cancer Cancer Immunotherapy Cardiomyopathy Infliximab Systematic review Atopic dermatitis Axial spondyloarthritis Autoimmunity ASDAS Antibiotic resistance Anti-TNF Alcohol Antimicrobials Meta-Analysis Cardio-oncology Vigibase® Méta-Analyse Access to care Apre-milast Spondyloarthritis Endocrine toxicity Etanercept Ankylosing Ustekinumab Drug survival Regulatory science Biologic drug Patient safety Angiotensin receptor blockers Sacroiliitis Drug reaction Network meta-analysis Sipuleucel-T Primary adrenal insufficiency Dermatology Immune-related adverse events Placebo Arrhythmia Management Aging Epidemiology Quality of life Ankylosing spondylitis Graft-versus-host disease Addiction Alitretinoin Pregnancy Abus d'antibiotiques Biosimilar Pharmaceuticals Biologic COVID-19 Azathioprine Acute Myeloid Leukaemia AML Anti-HCV Direct Acting Antivirals DAA Psoriasis Antimicrobial resistance Pharmaco-Épidémiologie Amyloidosis Ethics Intensive care Biologic therapy Adalimumab Pharmacovigilance Immune checkpoint inhibitors Auto-Diagnostic Stability Bacterial Beta-lactam antibiotics Cardiotoxicity Anxiety Treatment ArtThese Psoriatic arthritis Adverse side effects Bacterial rhinosinusitis Anticancer drugs Anxiété Antimicrobial Stewardship Adolescent Biologics Pharmacoepidemiology Angiotensin-converting enzyme inhibitors Auto-immune hepatitis Antibiotic misuse Apremilast Cohort studies Arthritis Antimicrobiens BTK protein Antibiotics Anti-Bacterial Agents Spondylitis Atrial fibrillation Glucocorticoids

 

 

 

Epidemiology in Dermatology and Evaluation of therapeutics , EA 7379

Adresse

Université Paris-Est Créteil Val de Marne (UPEC)

Campus Centre de Créteil
61 Avenue du Général de Gaulle
94010 Créteil Cedex

Courriel

emilie.sbidian@aphp.fr

Site Internet

 

Rattachement(s)

UFR de Santé

Direction

Émilie SBIDIAN

 

Axe(s) de recherche

 


[legende-image]65[/legende-image] Axe 1 : Comment mieux gérer les patients ayant développé des réactins graves aux médicaments, notamment en leur indiquant comment utiliser correctement les agents


[legende-image]65[/legende-image] Axe 2 : Rechercher les facteurs associés aux effets indesirables et à l'efficacité du médicament

 
 

COLLABORATIONS